Study Summary
An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
LUCAR-20S CAR-T cellsDRUG
An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Oncology Department，The First Affiliated Hospital of USTC west district | Hefei | Anhui | China |
| Hematological Department, People's Hospital of Jiangsu Province | Nanjing | Jiangsu | China |
| Hematological Department，Beijing Boren Hospital | Beijing | China |